Study guide

9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

ANCC Family Nurse Practitioner FNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy

2 Assessment Foundations

2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules

3 Function, Risk, and Lifespan Assessment

3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment

4 Diagnosis Foundations

4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change

5 Differential Diagnosis

5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps

6 Prevention and Anticipatory Guidance

6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan

7 Guidelines, Culture, and Evidence

7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal

8 Care Plans and Shared Decisions

8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions

9 Pharmacotherapeutics

9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety

10 Cardiovascular Primary Care

10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues

11 Respiratory Primary Care

11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care

12 Endocrine and Metabolic Primary Care

12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease

13 Gastrointestinal Primary Care

13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care

14 GU, Renal, and Reproductive Primary Care

14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function

15 HEENT, Skin, and Musculoskeletal

15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care

16 Neuro, Psych, Heme, Immune, and Infection

16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives

17 Clinical Delivery Skills

17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation

18 Professional Practice

18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role

19 Outcome Evaluation

19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy

20 Follow-Up, Systems, and Exam Strategy

20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review

9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics

Key Takeaways Explain This Topic AI

Steady state and washout each take about four to five half-lives — do not call a long-half-life drug a failure on day three, and do not assume it is gone the day after the last dose.

Codeine and tramadol are CYP2D6 prodrugs: poor metabolizers get little analgesia; ultrarapid metabolizers can produce toxic morphine, especially in children and in breastfed infants.

Test HLA-B 5701 before abacavir and never rechallenge a positive result; screen HLA-B 1502 before carbamazepine in at-risk East and South Asian ancestry because of SJS/TEN.

Clopidogrel needs CYP2C19 to become active — a known poor metabolizer needs an alternative P2Y12 plan with cardiology, not a silent default prescription.

Low albumin in older or malnourished adults raises the free fraction of highly bound drugs such as warfarin and phenytoin; a 'normal' total level can still be toxic.

Last updated: August 2026

The current FNP-BC Test Content Outline places pharmacotherapeutics, pharmacokinetics, pharmacodynamics, and pharmacogenetics in Domain III Planning . Implementation then tests pharmacotherapeutic intervention — interactions and contraindications (Section 9.2). This is the mechanism chapter. Cardiovascular, endocrine, and infection chapters later assume you can already predict what a CYP isoform, a falling eGFR, or a 2D6 phenotype will do to a named drug.

Pharmacokinetics is what the body does to the drug

Absorption is how a dose reaches blood. Food, gastric pH, chelation, gut edema, and first-pass extraction all change it. Doxycycline and fluoroquinolones bind divalent cations — calcium, iron, magnesium, sucralfate, and many antacids — so a casual "take it with milk" instruction can convert a working anti-infective into a subtherapeutic one. Separate those doses by several hours. First-pass metabolism is why sublingual nitroglycerin exists: an oral nitrate would be extracted by the liver before it reached the coronaries. Drugs with high first-pass (propranolol, oral morphine) have much larger oral than intravenous doses. Switching route without converting the dose is an Implementation error, not a rounding issue.

Distribution is where the drug goes after it is in plasma. Highly protein-bound drugs — warfarin, phenytoin, diazepam, valproate — ride on albumin. Older adults, people with malnutrition, nephrotic syndrome, or decompensated cirrhosis run low albumin . Total phenytoin can look "in range" while the free fraction is already toxic. Do not increase a highly bound drug just because a total level is low until you know the albumin or a free level. Volume of distribution also rises in pregnancy (more plasma volume) and in obesity; some loading doses scale with weight and some maintenance doses do not. Read the label for that molecule instead of inventing a universal milligram-per-kilogram rule for adults.

Metabolism is mostly hepatic cytochrome P450. Three isoforms carry almost every FNP genetics item:

CYP / pathway High-yield substrates What the FNP does

CYP3A4 (most common isoform) Simvastatin, lovastatin, many dihydropyridine calcium-channel blockers, midazolam Do not stack with strong inhibitors : clarithromycin, itraconazole, ketoconazole, ritonavir, large-volume grapefruit

CYP2D6 Codeine, tramadol, tamoxifen, many antidepressants, metoprolol Phenotype changes prodrug activation and parent-drug clearance

CYP2C19 Clopidogrel (needs activation), some PPIs Poor metabolizers form less active clopidogrel

Inducers — rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort — speed clearance and drop substrate levels, including combined oral contraceptives. Inhibitors raise substrate levels. Azithromycin is a weak 3A4 player compared with clarithromycin or erythromycin; if the stem offers both a macrolide and an azole, the strong inhibitor is the one that wrecks the statin.

Excretion is largely renal for many ACE inhibitors, metformin, gabapentin, lithium, and a long list of antibiotics. eGFR , not a "normal" creatinine in an 82-year-old with almost no muscle, is the dosing number. A creatinine of 0.7 mg/dL in a frail 48-kg woman is not proof of a youthful kidney. If the label uses creatinine clearance, calculate it. Dose-adjust or choose another agent when clearance falls; do not copy the middle-aged eGFR-90 dose into the frail-elderly box (Section 9.3).

Half-life and steady state

Elimination half-life is the time for plasma concentration to fall by half after distribution is finished. Steady state on a regular schedule arrives in about four to five half-lives . That is why levothyroxine is rechecked around six weeks, why lithium or an SSRI is not declared a failure on day three, and why missing a week of fluoxetine is not the same as missing a week of paroxetine or venlafaxine (short-half-life withdrawal). After you stop a drug it also takes about four to five half-lives to clear. Plan washouts and "when will this be gone?" answers with that clock, not with a calendar guess.

Pharmacodynamics is what the drug does to the body

An agonist binds a receptor and activates it (a mu-opioid agonist; albuterol at beta-2). A partial agonist activates less than a full agonist and can blunt a full agonist already on board (buprenorphine at mu receptors). An antagonist occupies the receptor and blocks the agonist: naloxone, beta blockers, ondansetron at 5-HT3. Competitive antagonists can be overcome by more agonist; noncompetitive ones cannot. Exam stems that ask why naloxone must sometimes be redosed are asking you to compare half-lives (the agonist may outlast the antagonist), not to recite a brand name.

Therapeutic index is the gap between a helpful concentration and a toxic one. Narrow-index drugs — warfarin, lithium, digoxin, phenytoin, carbamazepine, theophylline — need a level or a close surrogate (INR) and a low threshold to recheck after any new inhibitor, inducer, or change in albumin or eGFR. A wide-index drug can still harm; it just tolerates a small dose change more often.

Pharmacogenetics the FNP must act on

Codeine is a prodrug. CYP2D6 O-demethylates it to morphine . A poor metabolizer makes little morphine and gets no analgesia — do not "just give more codeine." An ultrarapid metabolizer makes excess morphine: respiratory depression, deaths in children after tonsillectomy, and toxicity in breastfed infants of ultrarapid mothers. FDA contraindicates codeine after pediatric tonsillectomy or adenoidectomy and warns against use while breastfeeding. Tramadol is also 2D6-activated. When the phenotype is unknown and the patient is a child, pick a non-prodrug analgesic.

Clopidogrel is a prodrug that CYP2C19 must activate. Poor metabolizers form less of the active thiol metabolite and have more stent thrombosis and recurrent ischemic events. If 2C19 poor-metabolizer status is already on the chart, do not leave the visit on default clopidogrel. Arrange an alternative P2Y12 inhibitor that does not depend on 2C19 activation, with cardiology — not a silent dose increase as your only move.

HLA-B*5701 predicts abacavir hypersensitivity : fever, rash, and respiratory or gastrointestinal symptoms that worsen on rechallenge and can kill. Screen before the first dose . A positive result is an absolute never-start and never-rechallenge.

HLA-B*1502 is linked to carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis , with higher prevalence in some Han Chinese, Thai, and other East and South Asian ancestry groups. FDA labeling recommends screening at-risk ancestry before carbamazepine. A positive allele means do not start. Do not use ancestry as a stereotype in place of the test when the label calls for the allele, and do not skip the question in a patient whose family origin is in a high-prevalence group. Related aromatic anticonvulsants can share risk; if the stem is carbamazepine plus ancestry, the allele is the Planning step.

  • Gene / pathway Drug FNP action
  • CYP2D6 ultrarapid Codeine, tramadol Avoid — morphine/opioid toxicity, including in a breastfed infant
  • CYP2D6 poor Codeine, tramadol Little analgesia; choose a different agent
  • CYP2C19 poor Clopidogrel Reduced activation; alternative P2Y12 with cardiology
  • HLA-B*5701 Abacavir Test before first dose; never start or rechallenge if positive
  • HLA-B*1502 Carbamazepine Screen at-risk ancestry; do not start if positive (SJS/TEN)
  • CYP3A4 strong inhibition Simvastatin, lovastatin Hold or switch the statin if the inhibitor is unavoidable

Vignette. A 34-year-old woman of Han Chinese ancestry presents with new trigeminal neuralgia. The correct Planning step before carbamazepine is HLA-B*1502 (or a drug that does not carry this allele risk), not "start low and see whether a rash appears." A 62-year-old week after coronary stent who is a documented CYP2C19 poor metabolizer should not leave primary care on default clopidogrel without a written cardiology plan.

Exam trap. PK/PD items hide in ordinary stems. "Why is this older adult sedated on a usual diazepam dose?" is low albumin plus a long-half-life benzodiazepine. "Why no pain relief from codeine?" is 2D6 poor metabolism. "Why did simvastatin myopathy start the day clarithromycin began?" is CYP3A4 inhibition. Planning chooses the molecule and the monitoring clock from the mechanism. Implementation is refusing the pair the mechanism predicts will harm.

Loading diagram... From dose to FNP action: PK, PD, and genotype